Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | HPGD | P15428 | 4/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | PDXK | O00764 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.56 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.54 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445658 | 1.00 | KDM4E (0.63) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL3442719 | 0.81 | KDM4E (0.70) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL1049253 | 0.79 | KDM4E (0.68) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Hydrochloric Acid SCHEMBL29733341 | 0.78 | KDM4E (0.66) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL30267871 | 0.78 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL2322958 | 0.78 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Hydrochloric Acid SCHEMBL191715 | 0.78 | KDM4E (0.66) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL30877002 | 0.78 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL3506 | 0.78 | HPGD (1.00) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Pyridoxine SCHEMBL3497798 | 0.76 | HPGD (0.96) | KDM4EALDH1A1HPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028470-A1 | Detection and Treatment of Schizophrenia | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2011-02-03 | — | — | US | claimed |
| US-20070123577-A1 | Inhibitor of protein modification products formation | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2007-05-31 | — | — | US | claimed |
| EP-1693369-A1 | PROTEIN MODIFIER PRODUCTION INHIBITOR | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2006-08-23 | — | — | EP | claimed |
| EP-0044940-B1 | AMINO-DESOXY-1.4;3.6-DIANHYDRO-HEXITE NITRATES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | Dr. Willmar Schwabe GmbH & Co. (DE) | 1984-09-19 | — | — | EP | claimed |
| US-4363805-A | TREATMENT OF CORONARY DISEASE | FIRMA WILLMAR SCHWABE (DE) | 1982-12-14 | — | — | US | claimed |
| JP-1199946-A | — | — | None | — | — | JP | disclosed |
| EP-2552202-B1 | METHODS AND COMPOSITIONS FOR WEIGHT LOSS | SDG INC (US) | 2023-07-26 | — | — | EP | disclosed |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2022-12-06 | — | — | US | disclosed |
| EP-3391876-B1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | SDG INC (US) | 2020-12-31 | — | — | US | disclosed |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | SDG, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | SDG INC (US) | 2020-08-20 | — | — | US | disclosed |
| EP-0274467-B1 | HEPATOCYTE DIRECTED VESICLE DELIVERY SYSTEM | GEHO, W., Blair (US) | 1992-05-20 | — | — | EP | disclosed |
| JP-H01199946-A | PYRIDOXYL HYDRAZONE DERIVATIVE AND PHARMACEYUTICAL COMPOSITION CONTAINING IT | YISSUM RES DEV CO OF HEBREW UNIV OF JERUSALEM | 1989-08-11 | — | — | JP | disclosed |
| EP-0315434-A2 | Pyridoxal hydrazone derivatives their production and use and pharmaceutical compositions containing the same | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1989-05-10 | — | — | EP | disclosed |
| EP-0274467-A1 | HEPATOCYTE DIRECTED VESICLE DELIVERY SYSTEM. | BLAIR GEHO W (US) | 1988-07-20 | — | — | EP | disclosed |
| EP-0274467-A4 | HEPATOCYTE DIRECTED VESICLE DELIVERY SYSTEM. | BLAIR GEHO W (US) | 1988-06-16 | — | — | EP | disclosed |
| WO-1988000474-A1 | HEPATOCYTE DIRECTED VESICLE DELIVERY SYSTEM | BLAIR GEHO W (US) | 1988-01-28 | — | — | WO | disclosed |
| US-4603044-A | USING CONNECTOR MOLECULE HAVING HYDROPHILIC AND CIPOPHILIC PORTIONS FOR TARGETER DRUG DELIVERY | TECHNOLOGY UNLIMITED, INC. (US) | 1986-07-29 | — | — | US | disclosed |
| US-4363805-A | TREATMENT OF CORONARY DISEASE | FIRMA WILLMAR SCHWABE (DE) | 1982-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123577-A1 | Inhibitor of protein modification products formation | SERPINB6, PROC, PLPBP | KDM4E 2177/4885ALDH1A1 3582/4885HPGD 699/4885 |
| US-20110028470-A1 | Detection and Treatment of Schizophrenia | GLO1, CBR1, AOX1 | KDM4E 1357/4885ALDH1A1 240/4885HPGD 117/4885 |
| US-11517529-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | KDM4E 4789/4885ALDH1A1 2309/4885HPGD 1531/4885 |
| US-20200405638-A1 | ORALLY BIOAVAILABLE LIPID-BASED CONSTRUCTS | FABP2, FABP1, FABP6 | KDM4E 4789/4885ALDH1A1 2309/4885HPGD 1531/4885 |
| US-20200261363-A1 | LIPID CONSTRUCT FOR DELIVERY OF INSULIN TO A MAMMAL | INSR, IAPP, GPR119 | KDM4E 4661/4885ALDH1A1 4198/4885HPGD 3818/4885 |
| US-10751418-B2 | Orally bioavailable lipid-based constructs | FABP2, FABP1, FABP6 | KDM4E 4789/4885ALDH1A1 2309/4885HPGD 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.